170 related articles for article (PubMed ID: 23980083)
1. Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation.
Valentini A; Finch A; Lubinski J; Byrski T; Ghadirian P; Kim-Sing C; Lynch HT; Ainsworth PJ; Neuhausen SL; Greenblatt E; Singer C; Sun P; Narod SA
J Clin Oncol; 2013 Nov; 31(31):3914-9. PubMed ID: 23980083
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.
Reding KW; Bernstein JL; Langholz BM; Bernstein L; Haile RW; Begg CB; Lynch CF; Concannon P; Borg A; Teraoka SN; Törngren T; Diep A; Xue S; Bertelsen L; Liang X; Reiner AS; Capanu M; Malone KE;
Breast Cancer Res Treat; 2010 Sep; 123(2):491-8. PubMed ID: 20135344
[TBL] [Abstract][Full Text] [Related]
3. Age-related decline in DNA repair function explains diminished ovarian reserve, earlier menopause, and possible oocyte vulnerability to chemotherapy in women with BRCA mutations.
Oktay K; Moy F; Titus S; Stobezki R; Turan V; Dickler M; Goswami S
J Clin Oncol; 2014 Apr; 32(10):1093-4. PubMed ID: 24550421
[No Abstract] [Full Text] [Related]
4. The incidence of cardiomyopathy in BRCA1 and BRCA2 mutation carriers after anthracycline-based adjuvant chemotherapy.
Pearson EJ; Nair A; Daoud Y; Blum JL
Breast Cancer Res Treat; 2017 Feb; 162(1):59-67. PubMed ID: 28066861
[TBL] [Abstract][Full Text] [Related]
5. Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Gronwald J; Robidoux A; Kim-Sing C; Tung N; Lynch HT; Foulkes WD; Manoukian S; Ainsworth P; Neuhausen SL; Demsky R; Eisen A; Singer CF; Saal H; Senter L; Eng C; Weitzel J; Moller P; Gilchrist DM; Olopade O; Ginsburg O; Sun P; Huzarski T; Lubinski J; Narod SA;
Breast Cancer Res Treat; 2014 Jul; 146(2):421-7. PubMed ID: 24951267
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.
King MC; Wieand S; Hale K; Lee M; Walsh T; Owens K; Tait J; Ford L; Dunn BK; Costantino J; Wickerham L; Wolmark N; Fisher B;
JAMA; 2001 Nov; 286(18):2251-6. PubMed ID: 11710890
[TBL] [Abstract][Full Text] [Related]
7. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Metcalfe K; Lynch HT; Ghadirian P; Tung N; Olivotto I; Warner E; Olopade OI; Eisen A; Weber B; McLennan J; Sun P; Foulkes WD; Narod SA
J Clin Oncol; 2004 Jun; 22(12):2328-35. PubMed ID: 15197194
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.
Phillips KA; Milne RL; Rookus MA; Daly MB; Antoniou AC; Peock S; Frost D; Easton DF; Ellis S; Friedlander ML; Buys SS; Andrieu N; Noguès C; Stoppa-Lyonnet D; Bonadona V; Pujol P; McLachlan SA; John EM; Hooning MJ; Seynaeve C; Tollenaar RA; Goldgar DE; Terry MB; Caldes T; Weideman PC; Andrulis IL; Singer CF; Birch K; Simard J; Southey MC; Olsson HL; Jakubowska A; Olah E; Gerdes AM; Foretova L; Hopper JL
J Clin Oncol; 2013 Sep; 31(25):3091-9. PubMed ID: 23918944
[TBL] [Abstract][Full Text] [Related]
9. Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom.
Shanley S; McReynolds K; Ardern-Jones A; Ahern R; Fernando I; Yarnold J; Evans G; Eccles D; Hodgson S; Ashley S; Ashcroft L; Tutt A; Bancroft E; Short S; Smith I; Gui G; ; Barr L; Baildam A; Howell A; Royle G; Pierce L; Easton D; Eeles R
Clin Cancer Res; 2006 Dec; 12(23):7033-8. PubMed ID: 17145825
[TBL] [Abstract][Full Text] [Related]
10. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane.
Fornier MN; Modi S; Panageas KS; Norton L; Hudis C
Cancer; 2005 Oct; 104(8):1575-9. PubMed ID: 16134178
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians.
Peshkin BN; Isaacs C; Finch C; Kent S; Schwartz MD
J Clin Oncol; 2003 Dec; 21(23):4322-8. PubMed ID: 14645421
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update.
Gronwald J; Tung N; Foulkes WD; Offit K; Gershoni R; Daly M; Kim-Sing C; Olsson H; Ainsworth P; Eisen A; Saal H; Friedman E; Olopade O; Osborne M; Weitzel J; Lynch H; Ghadirian P; Lubinski J; Sun P; Narod SA;
Int J Cancer; 2006 May; 118(9):2281-4. PubMed ID: 16331614
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy-induced amenorrhea, menopause-specific quality of life, and endocrine profiles in premenopausal women with breast cancer who received adjuvant anthracycline-based chemotherapy: a prospective cohort study.
Yoo C; Yun MR; Ahn JH; Jung KH; Kim HJ; Kim JE; Park JY; Park KO; Yoon DH; Kim SB
Cancer Chemother Pharmacol; 2013 Sep; 72(3):565-75. PubMed ID: 23842722
[TBL] [Abstract][Full Text] [Related]
14. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.
Metcalfe KA; Lynch HT; Ghadirian P; Tung N; Olivotto IA; Foulkes WD; Warner E; Olopade O; Eisen A; Weber B; McLennan J; Sun P; Narod SA
Gynecol Oncol; 2005 Jan; 96(1):222-6. PubMed ID: 15589605
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation.
Kotsopoulos J; Gronwald J; Huzarski T; Aeilts A; Randall Armel S; Karlan B; Singer CF; Eisen A; Tung N; Olopade O; Bordeleau L; Eng C; Foulkes WD; Neuhausen SL; Cullinane CA; Pal T; Fruscio R; Lubinski J; Metcalfe K; Sun P; Narod SA;
Breast Cancer Res Treat; 2023 Sep; 201(2):257-264. PubMed ID: 37432545
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy-induced amenorrhea and the resumption of menstruation in premenopausal women with hormone receptor-positive early breast cancer.
Koga C; Akiyoshi S; Ishida M; Nakamura Y; Ohno S; Tokunaga E
Breast Cancer; 2017 Sep; 24(5):714-719. PubMed ID: 28243992
[TBL] [Abstract][Full Text] [Related]
17. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Narod SA; Dubé MP; Klijn J; Lubinski J; Lynch HT; Ghadirian P; Provencher D; Heimdal K; Moller P; Robson M; Offit K; Isaacs C; Weber B; Friedman E; Gershoni-Baruch R; Rennert G; Pasini B; Wagner T; Daly M; Garber JE; Neuhausen SL; Ainsworth P; Olsson H; Evans G; Osborne M; Couch F; Foulkes WD; Warner E; Kim-Sing C; Olopade O; Tung N; Saal HM; Weitzel J; Merajver S; Gauthier-Villars M; Jernstrom H; Sun P; Brunet JS
J Natl Cancer Inst; 2002 Dec; 94(23):1773-9. PubMed ID: 12464649
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.
Rennert G; Bisland-Naggan S; Barnett-Griness O; Bar-Joseph N; Zhang S; Rennert HS; Narod SA
N Engl J Med; 2007 Jul; 357(2):115-23. PubMed ID: 17625123
[TBL] [Abstract][Full Text] [Related]
19. [Relationship of clinicopathological features and chemotherapeutic outcomes in women with BRCA1 and BRCA2 mutation-negative familial breast cancer].
Zhang J; Sun J; Ouyang T; Li JF; Wang TF; Fan ZQ; Fan T; Lin BY; Xie YT
Zhonghua Zhong Liu Za Zhi; 2016 Mar; 38(3):185-9. PubMed ID: 26988823
[TBL] [Abstract][Full Text] [Related]
20. The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study.
Segev Y; Iqbal J; Lubinski J; Gronwald J; Lynch HT; Moller P; Ghadirian P; Rosen B; Tung N; Kim-Sing C; Foulkes WD; Neuhausen SL; Senter L; Singer CF; Karlan B; Ping S; Narod SA;
Gynecol Oncol; 2013 Jul; 130(1):127-31. PubMed ID: 23562522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]